Comparative Pharmacology
Head-to-head clinical analysis: SULSOXIN versus THIOSULFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULSOXIN versus THIOSULFIL.
SULSOXIN vs THIOSULFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs) and disrupting peptidoglycan cross-linking.
Thiosulfil (sulfamethizole) is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis and thereby nucleic acid production.
500 mg orally 4 times daily for 10-14 days (or 1 g orally 4 times daily for severe infections).
500 mg orally twice daily for 10-14 days.
None Documented
None Documented
8 hours (terminal) — extends in renal impairment (up to 24 hours in CrCl <30 mL/min); requires dose adjustment
Terminal elimination half-life is 2-4 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to 20-50 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70% (unchanged); biliary/fecal: 20%; minor hepatic metabolism (<10%)
Renal: 70-90% as unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic